Menu
Recruiting NCT04468932

Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy

No phase Interventional Palsy Supranuclear Supranuclear Palsy, Progressive

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Repetitive transcranial magnetic stimulation (rTMS).
Who it may be relevant to
Registry conditions: Palsy Supranuclear, Supranuclear Palsy, Progressive. Basic parameters: 40 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Cerebellar Transcranial Magnetic Stimulation for Motor Control in Progressive Supranuclear Palsy

Overview

The objective of this proposal is to investigate the effect of non-invasive repetitive cerebellar transcranial magnetic stimulation (rTMS) on motor control in progressive supranuclear (PSP). The central hypothesis is that augmenting cerebellar inhibition via cerebellar rTMS will decrease postural instability in patients with PSP. We will use functional near infrared spectroscopy (fNIRS) to examine changes in motor and premotor cortical activity after cerebellar rTMS.

Interventions

  • Device Repetitive transcranial magnetic stimulation (rTMS)
    Aim 1: To determine the clinical effects of rTMS targeting the cerebellum on postural instability in PSP. The hypothesis to be tested is that TMS augmentation of cerebellar inhibition will improve cerebellum-dependent balance symptoms of PSP for a period of time sufficient to improve rehabilitation outcomes. The investigators will measure a battery of objective posturography metrics and other measures of motor control, including sway and center of pressure changes to backward tilt and forward tr

Primary outcome measures

  • objective posturography [Time frame: assessed on 4 days during the 8 week study period]
Secondary outcome measures (2)
  • fNIRS [Time frame: assessed on 4 days during the 8 week study period]
  • speech analysis [Time frame: assessed on 4 days during the 8 week study period]

Eligibility criteria

Inclusion criteria

  • probable or possible PSP by the revised MDS PSP Criteria (Hoglinger 2017)
  • age 40-85 at time of screening
  • ability to understand and cooperate with simple instructions in English
  • ability to read at 6th grade reading level in English
  • ability to stand unassisted for at least 30 seconds and to be able walk independently with a walker
  • ability to refrain from new physical and speech therapy programs for the duration of the study
  • ability to remain on stable doses of any cholinergic, dopaminergic, serotonergic sedative or NMDA receptor antagonists for the duration of the study
  • females of child-bearing age must perform a urine pregnancy test and be on reliable birth control during the course of the study

Exclusion criteria

  • other significant neurological or vestibular disorders
  • presence of electrically, magnetically or mechanically activated implants or history of injurious metal exposure in eyes, head, or body

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Triple blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Oregon Health & Science University — Portland

Identifiers

NCT: NCT04468932 · STUDY0020341 · KL2TR002370 · P2CHD086844 · K23NS121402

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗